MedTrace Logo

Pregnenolone Sulfate an Early Marker of the Memory Loss in Alzheimer's Disease

NCT00912886 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2013-04-11

No results posted yet for this study

Summary

The steroid pregnenolone sulfate (PREGS) may be one of the factors responsible for the memory decline related to normal aging or associated with Alzheimer's disease (AD). The purpose of this study is to determine whether plasma levels of PREGS are decreased patients with at mild to moderate AD compared with AD-free control subjects matched for gender and age and to see whether they are inversely correlated with the severity of memory deficits in AD patients. The hypothesis is that blood levels of PREGS are decreased with advanced age and with the stage of AD that would be positively correlated with memory deficits. Therefore PREGS could be considered as an early marker of the memory deficits in AD.

Conditions

  • Alzheimer Disease

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Sebastien Weill-Engerer, MD · Assistance Publique - Hôpitaux de Paris Hôpital Rothschild

  • Yvette Akwa, PhD · INSERM U788

Eligibility

Min Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00912886 on ClinicalTrials.gov